Sweden's Recipharm has bought Sanofi's contract inhalation drug business plant in the UK
Recipharm, the Swedish pharmaceutical contract development and manufacturing organisation (CDMO), has acquired Sanofi's contract inhalation drug business plant in the UK.
Located in Holmes Chapel, Sanofi’s manufacturing centre and business provides Recipharm with a solid platform to take further advantage of the growing respiratory drug market.
The additional inhalation commercial drug product manufacturing capabilities complements services already offered by Recipharm’s inhalation development facility in the US.
Thomas Eldered, CEO of Recipharm, commented: “Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel of respiratory products.
"As an already successful CMO with several clients, we look forward to introducing new contracts to Holmes Chapel by utilising our growing franchise in development services."
As part of the transaction Sanofi have entered into a long-term supply agreement with Recipharm for the products which are manufactured at the facility, including its metered dose inhalers and nasal sprays.
The facility covers 125,000 m2 and employs more than 450 employees.
According to Research and Markets, the global revenue from the respiratory market is forecast to increase from $30.9 billion in 2016 to $41.3 billion in 2023, at a compound annual growth rate of 4.23%.1